Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study - Wikidata - awgldk - TriplyDB

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

http://www.wikidata.org/entity/Q36110582

about

Natalizumab in Multiple Sclerosis: Long-Term Management.The use of natalizumab for multiple sclerosis Evaluating the Safety of Medication Exposures During Pregnancy: A Case Study of Study Designs and Data Sources in Multiple Sclerosis.Treatment of multiple sclerosis during pregnancy - safety considerations.Natalizumab treatment of multiple sclerosis: new insights.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Pregnancy: Effect on Multiple Sclerosis, Treatment Considerations, and Breastfeeding.Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach.Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation.Disease activity following pregnancy-related discontinuation of natalizumab in MS.Natalizumab during pregnancy and lactation.Role of Family Planning in Women With Multiple Sclerosis in Switzerland: Results of the Women With Multiple Sclerosis Patient Survey

P2860

Q33754882-CE5A46CC-8AE0-4292-AB95-32FE034DD334 Q33879159-692E41C9-7B28-4CBA-AB47-F1FA5B31FF53 Q38653267-6464491F-C6A8-4B7F-A3A3-09F7F905E313 Q38883520-9DC79DB2-59D4-4DF3-8E13-E2A8D9CBDA04 Q39048568-1EA9F239-3781-458E-8C2A-F112F9D79FBE Q40061894-2F959769-2F58-47E3-B4F7-5EB2F844A512 Q46145241-52B99AC0-108A-4519-BFB3-0AE4DF553934 Q47678330-B34F728C-6696-401C-81BC-E3BE3D47DBAD Q48229886-A8D32002-0930-4DD6-9079-32991A91891D Q49590553-EE241123-5C87-4014-9E93-BAA7C91A9B05 Q50248872-AAE18753-BBA4-4E9F-AA19-0AE9B99A3843 Q58576027-53CCE729-FFC5-4374-8107-54B41D84168E

P2860

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

http://www.wikidata.org/entity/Q36110582

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Evaluation of pregnancy outcom ...... observational, follow-up study

@ast

Evaluation of pregnancy outcom ...... observational, follow-up study

@en

type

label

Evaluation of pregnancy outcom ...... observational, follow-up study

@ast

Evaluation of pregnancy outcom ...... observational, follow-up study

@en

prefLabel

Evaluation of pregnancy outcom ...... observational, follow-up study

@ast

Evaluation of pregnancy outcom ...... observational, follow-up study

@en

P1433

Q36110582-FA81A1ED-59D9-4D72-AD32-5F065FE126DD

P1476

Q36110582-F4324314-FBDE-441D-9383-8039206C1AA8

P2093

Q36110582-36057637-C8CC-42B5-AE98-93896329FBBC

Q36110582-7C4C538C-9D41-4CDF-A607-C4965E84F4B7

Q36110582-834491CB-4BB2-4C25-BDCE-14F5D2BE8C94

Q36110582-CC37A1F3-B540-4E38-9750-B013568648D7

Q36110582-E6C9FE3A-3F6E-4BE5-90B6-9EAA9E37E333

P2860

Q36110582-00238897-E061-4414-8FC7-BB46E9B8E64C

Q36110582-0ECC8C94-1476-4541-B654-9A459618A231

Q36110582-15D101F1-5534-4952-9306-E4027493C2A5

Q36110582-1C2D6E1C-9A2C-48E6-B701-E9EE4C155220

Q36110582-23BD143F-4EDC-4E9B-AA7E-4D77212469F4

Q36110582-3637DF59-638B-4501-AF5C-BCD8352B0278

Q36110582-367C2892-A0B1-47AC-922B-A495CF395CA7

Q36110582-39C9BC33-AE3E-4B61-8443-0B33DDF137A3

Q36110582-404879E2-B0C7-47D9-A84D-D65697BA2403

Q36110582-46CA4EDA-9780-459B-A301-3AAD85DB7173

P2888

Q36110582-23F901AE-BD70-4E86-91E5-2077281F92BE

P304

Q36110582-AD5A6428-7FC3-42D9-A950-1C0894DAFC30

P31

Q36110582-1D848BCF-53CB-44F0-B012-0F57F9E45A65

P356

Q36110582-9560B26E-E54E-4723-9E73-876F38D914C6

P433

Q36110582-93B78E72-77CF-4B47-A9B7-34AD51107662

P478

Q36110582-495208AC-B0BB-421F-8788-2DC8AEFF94DC

P577

Q36110582-068C9EDD-1C87-4841-A7A9-302F18E5D9DC

P6179

Q36110582-B6F9FF67-1A0D-467E-A917-9FA3A57A0F31

P698

Q36110582-0F32AFE7-0C2D-4ED3-A6AB-05E852ED77A8

P932

Q36110582-DEDD1CEA-6FCD-4F37-A3C2-BF018B7AEB48

P356

S12883-016-0674-4

P1433

P1476

Evaluation of pregnancy outcom ...... observational, follow-up study

@en

P2093

Gary Bloomgren

http://www.w3.org/2001/XMLSchema#string

Lynda M Cristiano

http://www.w3.org/2001/XMLSchema#string

Madé Wenten

http://www.w3.org/2001/XMLSchema#string

Sandra Richman

http://www.w3.org/2001/XMLSchema#string

Susan Friend

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development

Defective blood vessel development and pericyte/pvSMC distribution in alpha 4 integrin-deficient mouse embryos

Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice

Consequences of lack of beta 1 integrin gene expression in mice

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Epidemiology and natural history of inflammatory bowel diseases

The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study.

Births: final data for 2013.

Reporting birth defects surveillance data 1968-2003.

P2888

s12883-016-0674-4

P304

150

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12883-016-0674-4

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1005582172

http://www.w3.org/2001/XMLSchema#string

P698

27552976

http://www.w3.org/2001/XMLSchema#string

P932

4995778

http://www.w3.org/2001/XMLSchema#string